
Opinion|Videos|October 28, 2024
Treatment Considerations for PSMA-Positive mCRPC Patients
Author(s)Neal Shore, MD, FACS
Neal Shore, MD, FACS, highlights the exciting advancements in radioligand therapy for prostate cancer, noting that ongoing trials are exploring its use in various disease stages and settings, and emphasizes the importance of reviewing the VISION and FORE trial publications for further insights.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
2
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
3
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
4
Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery
5






